These results could be partially explained by the prior observation that anti-PD-L1 treatment induces the expansion of tumor-infiltrating CD4+ and CD8+ T-cell subsets that co-express activating (ICOS) and inhibitory (LAG-3, PD-1) molecules [28]. The gene discussed is ICOS; the disease is neoplasm.